Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

324 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers.
Frisoni GB, Boccardi M, Barkhof F, Blennow K, Cappa S, Chiotis K, Démonet JF, Garibotto V, Giannakopoulos P, Gietl A, Hansson O, Herholz K, Jack CR Jr, Nobili F, Nordberg A, Snyder HM, Ten Kate M, Varrone A, Albanese E, Becker S, Bossuyt P, Carrillo MC, Cerami C, Dubois B, Gallo V, Giacobini E, Gold G, Hurst S, Lönneborg A, Lovblad KO, Mattsson N, Molinuevo JL, Monsch AU, Mosimann U, Padovani A, Picco A, Porteri C, Ratib O, Saint-Aubert L, Scerri C, Scheltens P, Schott JM, Sonni I, Teipel S, Vineis P, Visser PJ, Yasui Y, Winblad B. Frisoni GB, et al. Among authors: herholz k. Lancet Neurol. 2017 Aug;16(8):661-676. doi: 10.1016/S1474-4422(17)30159-X. Epub 2017 Jul 11. Lancet Neurol. 2017. PMID: 28721928 Review.
Imaging markers for Alzheimer disease: which vs how.
Frisoni GB, Bocchetta M, Chételat G, Rabinovici GD, de Leon MJ, Kaye J, Reiman EM, Scheltens P, Barkhof F, Black SE, Brooks DJ, Carrillo MC, Fox NC, Herholz K, Nordberg A, Jack CR Jr, Jagust WJ, Johnson KA, Rowe CC, Sperling RA, Thies W, Wahlund LO, Weiner MW, Pasqualetti P, Decarli C; ISTAART's NeuroImaging Professional Interest Area. Frisoni GB, et al. Among authors: herholz k. Neurology. 2013 Jul 30;81(5):487-500. doi: 10.1212/WNL.0b013e31829d86e8. Neurology. 2013. PMID: 23897875 Free PMC article. Review.
Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.
Garibotto V, Herholz K, Boccardi M, Picco A, Varrone A, Nordberg A, Nobili F, Ratib O; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers. Garibotto V, et al. Among authors: herholz k. Neurobiol Aging. 2017 Apr;52:183-195. doi: 10.1016/j.neurobiolaging.2016.03.033. Neurobiol Aging. 2017. PMID: 28317648 Review.
Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.
Chiotis K, Saint-Aubert L, Boccardi M, Gietl A, Picco A, Varrone A, Garibotto V, Herholz K, Nobili F, Nordberg A; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers. Chiotis K, et al. Among authors: herholz k. Neurobiol Aging. 2017 Apr;52:214-227. doi: 10.1016/j.neurobiolaging.2016.07.012. Neurobiol Aging. 2017. PMID: 28317650 Review.
Clinical validity of presynaptic dopaminergic imaging with 123I-ioflupane and noradrenergic imaging with 123I-MIBG in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies in the context of a structured 5-phase development framework.
Sonni I, Ratib O, Boccardi M, Picco A, Herholz K, Nobili F, Varrone A; Geneva Task Force for the Roadmap of Alzheimer's Biomarkers. Sonni I, et al. Among authors: herholz k. Neurobiol Aging. 2017 Apr;52:228-242. doi: 10.1016/j.neurobiolaging.2016.04.026. Neurobiol Aging. 2017. PMID: 28317651 Review.
Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias.
Chételat G, Arbizu J, Barthel H, Garibotto V, Law I, Morbelli S, van de Giessen E, Agosta F, Barkhof F, Brooks DJ, Carrillo MC, Dubois B, Fjell AM, Frisoni GB, Hansson O, Herholz K, Hutton BF, Jack CR Jr, Lammertsma AA, Landau SM, Minoshima S, Nobili F, Nordberg A, Ossenkoppele R, Oyen WJG, Perani D, Rabinovici GD, Scheltens P, Villemagne VL, Zetterberg H, Drzezga A. Chételat G, et al. Among authors: herholz k. Lancet Neurol. 2020 Nov;19(11):951-962. doi: 10.1016/S1474-4422(20)30314-8. Lancet Neurol. 2020. PMID: 33098804 Review.
Astrocyte Biomarkers in Alzheimer's Disease.
Carter SF, Herholz K, Rosa-Neto P, Pellerin L, Nordberg A, Zimmer ER. Carter SF, et al. Among authors: herholz k. Trends Mol Med. 2019 Feb;25(2):77-95. doi: 10.1016/j.molmed.2018.11.006. Epub 2019 Jan 2. Trends Mol Med. 2019. PMID: 30611668 Review.
Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [11C]PIB and [18F]FDDNP PET images.
Tolboom N, van der Flier WM, Boverhoff J, Yaqub M, Wattjes MP, Raijmakers PG, Barkhof F, Scheltens P, Herholz K, Lammertsma AA, van Berckel BN. Tolboom N, et al. Among authors: herholz k. J Neurol Neurosurg Psychiatry. 2010 Aug;81(8):882-4. doi: 10.1136/jnnp.2009.194779. Epub 2010 Jun 11. J Neurol Neurosurg Psychiatry. 2010. PMID: 20543188
Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series.
Prestia A, Caroli A, Herholz K, Reiman E, Chen K, Jagust WJ, Frisoni GB; Translational Outpatient Memory Clinic Working Group; Alzheimer's Disease Neuroimaging Initiative. Prestia A, et al. Among authors: herholz k. Alzheimers Dement. 2013 Nov;9(6):677-86. doi: 10.1016/j.jalz.2012.09.016. Epub 2013 Jan 30. Alzheimers Dement. 2013. PMID: 23375562 Free PMC article.
324 results